Method for selecting chemotherapy for a patient with gastric cancer using combination of tegafur, gimeracil and potassium oteracil drugs and EGFR inhibitor
This invention provides a method for predicting a therapeutic effect of chemotherapy with a combination drug containing tegafur, gimeracil, and oteracil potassium in a gastric cancer patient, the method comprising the steps of: (1) measuring an expression level of EGFR contained in a biological sample obtained from the patient； (2) comparing the expression level of EGFR obtained in step (1) with a corresponding predetermined cut-off point； and (3) predicting that the patient is likely to sufficiently respond to chemotherapy in which a combination drug containing tegafur, gimeracil, and oteracil potassium is used in combination with an EGFR inhibitor, when the comparison in step (2) reveals that the expression level of EGFR is greater than the cut-off point, or predicting that the patient is likely to sufficiently respond to chemotherapy in which a combination drug containing tegafur, gimeracil, and oteracil potassium is used alone, when the comparison in step (2) reveals that the expression level of EGFR is not greater than the cut-off point.
